Incytevs.Regeneron
INCY vs REGN · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Regeneron is about 3.4× larger than Incyte by market cap; Incyte trades at the lower P/E (14.0 vs 17.7); year to date, Incyte leads (+14.9% vs −3.9%).
Side by side
| INCY | REGN | |
|---|---|---|
| Market cap | $22.5B | $76.4B |
| Price | $112.75 | $739.57 |
| Today | −0.6% | −0.3% |
| Return YTD | +14.9% | −3.9% |
| Return 1Y | +30.1% | +27.2% |
| Since June 26, 2026 | −0.9% | +16.9% |
| P/E | 14.0 | 17.7 |
| P/S | 3.9 | 4.9 |
| P/B | 3.5 | 2.4 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
IncyteINCY
Jakafi in myelofibrosis and Opzelura in dermatology anchor a portfolio split between cancer and inflammation.
Full INCY profile →RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →More INCY & REGN comparisons
Other head-to-heads in the Biotech & innovation segment.